These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 35942602)
41. Cefazolin versus anti-staphylococcal penicillins for treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a narrative review. Loubet P; Burdet C; Vindrios W; Grall N; Wolff M; Yazdanpanah Y; Andremont A; Duval X; Lescure FX Clin Microbiol Infect; 2018 Feb; 24(2):125-132. PubMed ID: 28698037 [TBL] [Abstract][Full Text] [Related]
42. Comparative outcomes of cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bacteraemia: a prospective multicentre cohort study in Korea. Lee S; Song KH; Jung SI; Park WB; Lee SH; Kim YS; Kwak YG; Kim YK; Kiem SM; Kim HI; Kim ES; Park KH; Kim NJ; Jang HC; Kim HB; Clin Microbiol Infect; 2018 Feb; 24(2):152-158. PubMed ID: 28694202 [TBL] [Abstract][Full Text] [Related]
43. Efficacy of cloxacillin versus cefazolin for methicillin-susceptible Burdet C; Loubet P; Le Moing V; Vindrios W; Esposito-Farèse M; Linard M; Ferry T; Massias L; Tattevin P; Wolff M; Vandenesch F; Grall N; Quintin C; Mentré F; Duval X; Lescure FX; BMJ Open; 2018 Sep; 8(8):e023151. PubMed ID: 30173161 [TBL] [Abstract][Full Text] [Related]
44. Retrospective Analysis of Adverse Drug Events Between Nafcillin Versus Cefazolin for Treatment of Methicillin-Susceptible Chan L; Chan-Tompkins NH; Como J; Guarascio AJ Ann Pharmacother; 2020 Jul; 54(7):662-668. PubMed ID: 31888347 [No Abstract] [Full Text] [Related]
45. Effectiveness and Safety of Ceftriaxone Compared to Standard of Care for Treatment of Bloodstream Infections Due to Methicillin-Susceptible Alsowaida YS; Benitez G; Bin Saleh K; Almangour TA; Shehadeh F; Mylonakis E Antibiotics (Basel); 2022 Mar; 11(3):. PubMed ID: 35326838 [TBL] [Abstract][Full Text] [Related]
46. Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort. Herrera-Hidalgo L; Muñoz P; Álvarez-Uría A; Alonso-Menchén D; Luque-Marquez R; Gutiérrez-Carretero E; Fariñas MDC; Miró JM; Goenaga MA; López-Cortés LE; Angulo-Lara B; Boix-Palop L; de Alarcón A; Int J Infect Dis; 2023 Dec; 137():134-143. PubMed ID: 37926195 [TBL] [Abstract][Full Text] [Related]
47. Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections among 122 hospitals. McDanel JS; Perencevich EN; Diekema DJ; Herwaldt LA; Smith TC; Chrischilles EA; Dawson JD; Jiang L; Goto M; Schweizer ML Clin Infect Dis; 2015 Aug; 61(3):361-7. PubMed ID: 25900170 [TBL] [Abstract][Full Text] [Related]
48. Is cefazolin inferior to nafcillin for treatment of methicillin-susceptible Staphylococcus aureus bacteremia? Lee S; Choe PG; Song KH; Park SW; Kim HB; Kim NJ; Kim EC; Park WB; Oh MD Antimicrob Agents Chemother; 2011 Nov; 55(11):5122-6. PubMed ID: 21825299 [TBL] [Abstract][Full Text] [Related]
49. Cefazolin in the treatment of central nervous system infections: A narrative review and recommendation. Antosz K; Battle S; Chang J; Scheetz MH; Al-Hasan M; Bookstaver PB Pharmacotherapy; 2023 Jan; 43(1):85-95. PubMed ID: 36521869 [TBL] [Abstract][Full Text] [Related]
51. The Impact of Reporting a Prior Penicillin Allergy on the Treatment of Methicillin-Sensitive Staphylococcus aureus Bacteremia. Blumenthal KG; Shenoy ES; Huang M; Kuhlen JL; Ware WA; Parker RA; Walensky RP PLoS One; 2016; 11(7):e0159406. PubMed ID: 27438379 [TBL] [Abstract][Full Text] [Related]
52. Limitations of ceftriaxone compared with cefazolin against MSSA: an integrated pharmacodynamic analysis. Zelenitsky SA; Beahm NP; Iacovides H; Ariano RE; Zhanel G J Antimicrob Chemother; 2018 Jul; 73(7):1888-1894. PubMed ID: 29635472 [TBL] [Abstract][Full Text] [Related]
53. Prolonged cefazolin course for treatment of methicillin susceptible staphylococcus species infections and the impact on the emergence of multidrug-resistant bacteria during cloxacillin shortage. Vareil MO; Barret A; Vinclair C; Guerpillon B; Leyssene D; Jaouen AC; Alleman L; Wille H Infect Dis Now; 2021 May; 51(3):304-307. PubMed ID: 33934810 [TBL] [Abstract][Full Text] [Related]
54. Meta-analysis of trials comparing cefazolin to antistaphylococcal penicillins in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia. Rindone JP; Mellen CK Br J Clin Pharmacol; 2018 Jun; 84(6):1258-1266. PubMed ID: 29600576 [TBL] [Abstract][Full Text] [Related]
55. Adjunctive Daptomycin in the Treatment of Methicillin-susceptible Staphylococcus aureus Bacteremia: A Randomized, Controlled Trial. Cheng MP; Lawandi A; Butler-Laporte G; De l'Étoile-Morel S; Paquette K; Lee TC Clin Infect Dis; 2021 May; 72(9):e196-e203. PubMed ID: 32667982 [TBL] [Abstract][Full Text] [Related]
56. Cefazolin and Ertapenem, a Synergistic Combination Used To Clear Persistent Staphylococcus aureus Bacteremia. Sakoulas G; Olson J; Yim J; Singh NB; Kumaraswamy M; Quach DT; Rybak MJ; Pogliano J; Nizet V Antimicrob Agents Chemother; 2016 Nov; 60(11):6609-6618. PubMed ID: 27572414 [TBL] [Abstract][Full Text] [Related]
57. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Stryjewski ME; Szczech LA; Benjamin DK; Inrig JK; Kanafani ZA; Engemann JJ; Chu VH; Joyce MJ; Reller LB; Corey GR; Fowler VG Clin Infect Dis; 2007 Jan; 44(2):190-6. PubMed ID: 17173215 [TBL] [Abstract][Full Text] [Related]
58. Comparison of the efficacy of nafcillin and glycopeptides as definitive therapy for patients with methicillin-susceptible Staphylococcus aureus bacteremia: a retrospective cohort study. Oh DH; Kim JJ; Kim J; Seong H; Lee SJ; Kim YC; Kim EJ; Jung IY; Jeong WY; Jeong SJ; Ku NS; Han SH; Choi JY; Song YG; Kim JM BMC Infect Dis; 2018 Jan; 18(1):60. PubMed ID: 29378565 [TBL] [Abstract][Full Text] [Related]
59. Comparative effectiveness of cefazolin versus cloxacillin as definitive antibiotic therapy for MSSA bacteraemia: results from a large multicentre cohort study. Bai AD; Showler A; Burry L; Steinberg M; Ricciuto DR; Fernandes T; Chiu A; Raybardhan S; Science M; Fernando E; Tomlinson G; Bell CM; Morris AM J Antimicrob Chemother; 2015 May; 70(5):1539-46. PubMed ID: 25614044 [TBL] [Abstract][Full Text] [Related]
60. Daptomycin Plus Oxacillin for Persistent Methicillin-Susceptible Kufel WD; Zagoria Z; Blaine BE; Steele JM; Mahapatra R; Paolino KM; Thomas SJ Ann Pharmacother; 2024 Apr; 58(4):360-365. PubMed ID: 37542415 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]